Cell therapy for diabetes in transplant recipients

Stem cell-derived islet cells combined with immunosuppressive agents address the scarcity of donor islets and immune rejection, providing a sustainable treatment for diabetes by administering a composition of C-peptide-positive, NKX6.1-positive, ISL1-positive cells with agents like anti-thymocyte globulin to transplant recipients.

WO2026128361A1PCT designated stage Publication Date: 2026-06-18VERTEX PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
VERTEX PHARMACEUTICALS INC
Filing Date
2025-12-08
Publication Date
2026-06-18

Smart Images

  • Figure IMGF000091_0001
    Figure IMGF000091_0001
  • Figure IMGF000100_0001
    Figure IMGF000100_0001
  • Figure IMGF000101_0001
    Figure IMGF000101_0001
Patent Text Reader

Abstract

Disclosed herein are methods of treating a subject having diabetes with a population of stem cell-derived islet cells and one or more immunosuppressive reagents, such as an anti-thymocyte globulin binding moiety. The subject may have received an organ transplant.
Need to check novelty before this filing date? Find Prior Art